CD4 mAbs prevent progression of alloactivated CD4+ T cells into the S phase of the cell cycle without interfering with early activation signals.
Knowing that several CD4 mAbs may delay allograft rejection in the absence of circulating CD4+ lymphocyte depletion in vivo, we investigated the mechanisms whereby CD4 mAbs can interfere with the development of alloreactive T cells in the mixed lymphocyte reaction (MLR). In agreement with previous r...
Main Authors: | Fournel, S, Vincent, C, Assossou, O, Gorman, S, Robinet, E, Phillips, J, Flacher, M, Cordier, G, Waldmann, H, Revillard, J |
---|---|
Format: | Journal article |
Language: | English |
Published: |
1996
|
Similar Items
-
A noncomitogenic CD2R monoclonal antibody induces apoptosis of activated T cells by a CD95/CD95-L-dependent pathway.
by: Fournel, S, et al.
Published: (1998) -
A humanised therapeutic CD4 mAb inhibits TCR-induced IL-2, IL-4, and IL-10 secretion and expression of CD25, CD40L, and CD69.
by: Woods, M, et al.
Published: (1998) -
B cell depletion with anti-CD20 mAb exacerbates anti-donor CD4+ T cell responses in highly sensitized transplant recipients
by: Asuka Tanaka, et al.
Published: (2021-09-01) -
mAb therapy controls CNS‐resident lyssavirus infection via a CD4 T cell‐dependent mechanism
by: Kate E Mastraccio, et al.
Published: (2023-10-01) -
Combined use of RS61443 with CD4 and CD8 MAbs to generate tolerance to skin xenografts from rat to mouse.
by: Chen, Z, et al.
Published: (1994)